General Information of Drug (ID: DMX4PWV)

Drug Name
ASP1951 Drug Info
Synonyms PTZ-522
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMX4PWV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INCAGN01876 DMNUXKA Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
INCAGN1876 DM8XN4A Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
TRX-518 DMQS5DY Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
MK-4166 DML5V76 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
REGN6569 DM0ZMNI Squamous head and neck cell carcinom 2D60.0 Phase 1 [6]
AMG 228 DMLQJ5P Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
TRX518 DM9IDUH Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Agonist [1]

References

1 ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Agenus.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
5 Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
6 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
7 Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
8 Clinical pipeline report, company report or official report of Leap Therapeutics.